...
首页> 外文期刊>Journal of chromatography, A: Including electrophoresis and other separation methods >Optimization of a sensitive and robust strategy for micellar electrokinetic chromatographic analysis of sofosbuvir in combination with its co-formulated hepatitis C antiviral drugs
【24h】

Optimization of a sensitive and robust strategy for micellar electrokinetic chromatographic analysis of sofosbuvir in combination with its co-formulated hepatitis C antiviral drugs

机译:Sofosbuvir与其共产性丙型肝炎抗病毒药物相结合的胶束电动色谱分析敏感和鲁棒策略的优化

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Based on our previous work with "pseudostationary-ion exchanger sweeping", we use this strategy to develop a sensitive, reliable and robust method for the analysis of the newly-FDA approved hepatitis C antiviral drugs namely; sofosbuvir (SOV), daclatasvir (DAC), ledipasvir (LED) and velpatasvir (VEP) in their pure forms and co-formulated pharmaceutical dosage forms using micellar electrokinetic chromatography (MEKC) as a separation method. For the first time, a successful separation of all the investigated compounds was achieved in less than 8 min using a basic background electrolyte (BGE) composed of 25 mmol L-1 SDS + 20% (v/v) ACN (acetonitrile) in 10 mmol L-1 disodium tetraborate buffer (final apparent pH is 9.90). A special focus was given to optimize the composition of the sample matrix to maintain the solubility of the analytes within the sample zone while gaining additional benefits regarding analyte zone focusing. It was found that replacing phosphoric acid (as a sample matrix) with a zwitterionic/isoelectric buffering compound (L-glutamic acid) has a substantial positive impact on the obtained enrichment efficiency. The interplay of other enrichment principles such as the retention factor gradient effect (RFGE) is also discussed. A full validation study is performed based on the pharmacopeial and ICH guidelines. The obtained limits of detection and quantitation are as low as 0.63 and 1.3 mu g mL(-1); respectively for SOV and DAC and 1.3 and 2.5 mu g mL(-1); respectively for LED and VEP using UV-DAD as a detection method. The selectivity of the developed method for determination of the studied compounds in their pharmaceutical dosage forms or in the presence of ribavirin (RIB) or elbasvir (ELB), which are other prescribed medications in the treatment regimen of patients with hepatitis C virus infection, is demonstrated. It is shown that with acidic sample matrix and basic BGE, an efficient and precise approach was designed in which analyte adsorption on the capillary wall was minimized while keeping repeatable peak height, peak area and migration time together with the highest possible enrichment efficiency. (C) 2019 Elsevier B.V. All rights reserved.
机译:根据我们以前的“准固定离子交换清扫”工作,我们用这个策略来开发用于新经FDA批准即丙型肝炎抗病毒药物的分析灵敏,可靠和稳定的方法;索非布韦(SOV),达卡他韦(DAC),ledipasvir(LED)和velpatasvir(VEP)在使用胶束电动色谱(MEKC)作为分离方法其纯的形式和共同配制的药物剂型。对于第一次,所有研究的化合物的一个成功的分离在小于8分钟使用在10的25毫摩尔L-1 SDS + 20%(体积/体积)ACN(乙腈)组成的基本背景电解质(BGE)实现毫摩尔L-1四硼酸二钠缓冲液(最终表观pH为9.90)。被赋予了特殊焦点来优化样品基体的组成,以保持分析物的溶解度样品区中,同时获得关于分析物区域聚焦额外的好处。据发现,用两性离子/等电缓冲化合物(L-谷氨酸)取代磷酸(作为样品基质)对所获得的富集效率大幅积极的影响。的其他富集原则,如保留因子渐变效果(RFGE)的相互作用进行了讨论。一个完整的验证研究是基于药典和ICH指南进行。将所得到的检测和定量的限制是低到0.63和1.3亩克毫升(-1);分别为SOV和DAC和1.3和2.5亩克毫升(-1);分别用于LED和VEP使用UV-DAD作为检测方法。用于测定它们的药物剂型或利巴韦林(RIB)或elbasvir(ELB)的存在下,研究的化合物,这是在患者的丙型肝炎病毒感染的治疗方案的其它规定的药物的开发方法的选择性,是证明。结果表明,用酸性样品基质和基本BGE,一种有效和精确的方法被设计成在毛细管壁的分析物的吸附而具有最高可能的富集效率保持可重复的峰高,峰面积和迁移时间一起被最小化。 (c)2019 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号